Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu

(American Association for the Advancement of Science) In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news